medigraphic.com
Instituto Nacional de Salud Pública

2016, Number 2

<< Back Next >>

salud publica mex 2016; 58 (2)

Advances in the diagnosis and control of lymphomas

Candelaria M

Language: English
References: 37
Page: 296-301
PDF size: 215.58 Kb.


ABSTRACT

Lymphoproliferative disorders have increased in last decades. Immunohistochemistry analysis is required to categorize them in different clinical entities, as has been stablished by WHO. Advances in imaging have set the PET–CT as a standard staging procedure in most cases. Knowledge of the biology of these malignancies has allowed therapeutic advances with different approaches, including development of monoclonal antibodies, conjugated antibodies, immunomodulatory agents, as well as inhibition of specific pathways. Although new drugs are promising, the cost-benefit impact requires to be evaluated in pharmacoeconomic clinical trials.


REFERENCES

  1. Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical application. Blood 2011; 117 (19): 5019-5032.

  2. Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis CB, et al. Non-Hodgkin’s lymphomas. version 4.2014. J Natl Compr Canc Netw 2014; 12(9):1282-1303.

  3. Eichenauer DA, Engert A, André M, Federico M, Illidge T, Hutchings M, Ladetto M, ESMO Guidelines Working Group Hodgkin’s lymphoma. ESMO Clinical Practice Guidelines for diagnosis, treatment and followup. Ann Oncol 2014; 25 suppl 3:iii70-5. doi: 10.1093/annonc/mdu181

  4. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. Available at: http://globocan.iarc.fr

  5. Candelaria M, Cervera-Ceballos E, Meneses-García A, Avilés-Salas A, Lome-Maldonado C, Zarate-Osornio A, et al. Guías Nacionales de Diagnóstico y Tratamiento de Linfoma no Hodgkin. Revista de Investigación Clínica 2013; 65(suppl 2):S5-S26.

  6. Barrington S, Mikhaeel G, Kostakoglu L, Meignan M, Hutchings M, Mueller S, et al. Role of Imaging in the Staging and Response Assessment of Lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol 2014; 32: 3048-3058.

  7. El-Galaly TC, d’Amore F, Mylam KJ, de Nully Brown P, Bøgsted M, Bukh A, et al. Routine bone marrow biopsy has little or no therapeutic consequence for positron emission tomography/computed tomography–staged treatment-naive patients with Hodgkin lymphoma. J Clin Oncol 2012; 30: 4508-4514.

  8. Suresh T, Lee LX, Joshi J, Barta SK. New antibody approaches to lymphoma. J Hematol Oncol 2014; 9: 58.

  9. McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16: 2825-2833.

  10. Eichenauer D, Engert A. Antibodies and antibody-drug conjugates in the treatment of Hodgkin lymphoma. Eur J Hematol 2014; 93: 1-8.

  11. Mossner E, Brunker P, Moser S, Mossner E, Brunker P, Moser S, et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell- mediated B-cell cytotoxicity. Blood 2010; 115: 4393-4402.

  12. Morschhauser FA, Cartron G, Thieblemont C, Solal-Celigny P, Haioun C, Bouabdallah R, et al. Obinutuzumab (GA101) monotherapy in relapsed/ refractory diffuse large b-cell lymphoma or mantle-cell lymphoma: results from the phase II GAUGUIN study. J Clin Oncol 2013; 31: 2912-2919.

  13. Czuczman MS, Fayad L, Delwail V, Cartron G, Jacobsen E, Kuliczkowski K, et al. Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study. Blood 2012; 119: 3698-3704.

  14. Negrea GO, Elstrom R, Allen SL, Rai KR, Abbasi RM, Farber CM, et al. Subcutaneous injections of low- dose veltuzumab (humanized anti-CD20 antibody) are safe and active in patients with indolent non-Hodgkin’s lymphoma. Haematologica 2011; 96: 567-573.

  15. Leonard JP, Coleman M, Ketas JC, Chadburn A, Furman R, Schuster MW, et al. Epratuzumab, a humanized anti-CD22 antibody, in aggressive non- Hodgkin’s lymphoma: phase I/II clinical trial results. Clin Cancer Res 2004; 10: 5327-5334.

  16. Strauss SJ, Morschhauser F, Rech J, Repp R, Solal-Celigny P, Zinzani PL, et al. Multicenter phase II trial of immunotherapy with the humanized anti- CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin’s lymphoma. J Clin Oncol 2006; 24: 3880-3886.

  17. Hamadani M, Fanale MA, Bello CM, Kipps TJ, Offner F, Verhoef G, et al. Safety Profile and Clinical Response To MEDI-551, a Humanized Monoclonal Anti- CD19, In a Phase 1/2 Study In Adults With Relapsed Or Refractory Advanced B-Cell Malignancies. Blood 2013; 122: 1810.

  18. Fanale M, Assouline S, Kuruvilla J, Solal-Celigny P, Heo DS, Verhoef G, et al. Phase IA/II, multicentre, open-label study of the CD40 antagonistic monoclonal antibody lucatumumab in adult patients with advanced non- Hodgkin or Hodgkin lymphoma. Br J Haematol 2014; 164: 258-265.

  19. Law CL, Gordon KA, Collier J, Klussman K, McEarchern JA, Cerveny CG, et al. Preclinical antilymphoma activity of a humanized anti-CD40 monoclonal antibody, SGN-40. Cancer Res 2005; 65: 8331-8338.

  20. Ishida T, Ueda R. CCR4 as a novel molecular target for immunotherapy of cancer. Cancer Sci 2006; 97: 1139-1146.

  21. Ishida T, Joh T, Uike N, Yamamoto K, Utsunomiya A, Yoshida S, et al. Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study. J Clin Oncol 2012; 30: 837-842. 22 Bryan LJ, Gordon LI. Blocking tumor escape in hematologic malignancies: The anti-PD-1 strategy. Blood Rev 2015; 29: 25-32. 23 Moskowitz CH, Ribrag V, Michot JM. PD-1. Blockade with the Monoclonal Antibody Pembrolizumab (MK-3475) in Patients with Classical Hodgkin Lymphoma after Brentuximab Vedotin Failure: Preliminary Results from a Phase 1b Study. Blood 2014; 124:abstr 290.

  22. Stathis A, Younes A. The new therapeutical scenario of Hodgkin lymphoma. Ann Oncol 2015; 26: 2026-2033.

  23. Davids MS, Seymour JF, Gerecitano JF, Brad SK, Pagel JM, Wierda WG, et al. The Single-Agent Bcl-2 Inhibitor ABT-199 (GDC-0199) in patients with Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL): Responses Observed in All Mantle Cell Lymphoma (MCL) Patients. Blood 2013; 122:abstr 1789.

  24. Viardot A, Goebeler M, Noppeney R, Krause SW, Kallert S, Ferstl B, et al. Blinatumomab Monotherapy Shows Efficacy in Patients with Relapsed Diffuse Large B Cell Lymphoma. ASH Annu Meet Abstr 2011; 118: 1637.

  25. DelMonte A, Ghielmini M, Sessa C. Beyond monoclonal antibodies in Non-Hodgkin lymphoma. The Oncologist 2009; 14: 511-525.

  26. Robak T, Huang H, Jin J, Zhu J, Liu T, Samoilova O, et al. Bortezomibbased therapy for newly diagnosed mantle-cell lymphoma. N Engl J Med 2015; 372: 944-953.

  27. Sonali MS. New drugs for the treatment of Non-Hodgkin’s lymphomas. Chin Clin Oncol 2015; 4: 14-25.

  28. Whittaker SJ, Demierre MF, Kim EJ, Rook AH, Lerner A, Duvic M, et al. Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J Clin Oncol 2010; 28: 4485-4491.

  29. O’Connor OA, Masszi T, Kerry JS, Pinter-Brown LC, Foss FM, Popplewell L, et al. Belinostat, a novel pan-histone deacetylase inhibitor (HDACi), in relapsed or refractory peripheral T-cell lymphoma (R/ R PTCL): Results from the BELIEF trial. J Clin Oncol 2013; 31: abstr 8507.

  30. Avivi I, Goy A. Refining the Mantle Cell Lymphoma Paradigm: Impact of Novel Therapies on Current Practice. Clin Cancer Res 2015;21(17):3853- 3861.

  31. Witzig TE, Vose JM, Zinzani PL, Reeder CM, Buckstein R, Polikoff JA, et al. An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin’s lymphoma. Ann Oncol 2011; 22: 1622-1627.

  32. Mohamed AJ, Yu L, Bäckesjö CM, Vargas L, Faryal R, Aints A, et al. Bruton’s tyrosine 15. Kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain. Immunol Rev 2009; 228: 58-73.

  33. Advani RH, Buggy JJ, Sharman JP, Smith SM, Boyd TE, Grant B, et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol 2013; 31: 88-94.

  34. Courtney KD, Corcoran RB, Engelman JA. The PI3K pathway as drug target in human cancer. J Clin Oncol 2010; 28: 1075-1083.

  35. Yang Q, Modi P, Newcomb T, Quéva C, Gandhi V. Idelalisib: First-in-Class PI3K Delta inhibitor for the treatment of chronic lymphocytic leukemia, small lymphocytic leukemia, and follicular lymphoma. Clin Cancer Res 2015; 21:1537-1542. 38.Kahl BS, Spurgeon SE, Furman RR, Flinn IW, Coutre SE, Brown JR, et al. A phase 1 study of the PI3Kδ inhibitor idelalisib in patients with relapsed/ refractory mantle cell lymphoma (MCL). Blood 2014; 123: 3398-3405.

  36. Hewett YG, Uprety D, Shah BK. Idelalisib- a PI3Kδ targeting agent for B-cell malignancies. J Oncol Pharm Pract 2015; 23. pii: 1078155215572933.

  37. William BM, Hohenstein M, Loberiza FR, Caponetti GC, Bociek G, Bierman P, et al. Phase I/II Study of Dasatinib in Relapsed or Refractory Non- Hodgkin’s Lymphoma (NHL). Blood 2010;116:abstr 288.




2020     |     www.medigraphic.com